Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly director Gabrielle Sulzberger acquired 4.668 shares of common stock through a deferred compensation plan, increasing her beneficial ownership to 2,956.674 shares.

Summary

• Gabrielle Sulzberger, a Director of Eli Lilly & Co (LLY), acquired 4.668 shares of common stock.
• The transaction occurred on December 15, 2025, at a price of $1,062.19 per share.
• These shares were acquired by deferring cash compensation and converting it into stock units under the Lilly Directors' Deferral Plan.
• Following this transaction, Ms. Sulzberger's total beneficial ownership of Eli Lilly common stock increased to 2,956.674 shares.
• The acquired stock units will be settled in shares of common stock upon Ms. Sulzberger's separation from service with the company.

Sentiment

Score: 7

Explanation: The deferral of cash compensation into stock units by a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and its shareholders, indicating confidence in the company's future.

Positives

• The director's election to defer cash compensation into stock units demonstrates a strong alignment of her financial interests with the long-term performance and shareholder value of Eli Lilly & Co.
• Increasing insider ownership, even through deferred compensation, can signal confidence in the company's future prospects.

Future Outlook

The acquired stock units, resulting from deferred compensation, are scheduled to be settled in shares of common stock following the reporting person's separation from service with Eli Lilly & Co.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This type of deferred compensation plan, where corporate directors elect to receive equity instead of cash for their services, is a common and well-established practice across many large public companies, particularly in the pharmaceutical sector. It is designed to align the interests of the board members with the long-term strategic goals and shareholder value creation of the company.

Comparison to Industry Standards

• Many leading pharmaceutical and biotech companies, including Pfizer, Merck, and Johnson & Johnson, offer similar deferred compensation programs to their non-employee directors. These plans typically allow directors to defer all or a portion of their cash fees into company stock or stock units.
• The acquisition of 4.668 shares at a price of $1,062.19, totaling approximately $4,958, is consistent with typical compensation levels for non-executive directors at a company of Eli Lilly's market capitalization and industry standing, reflecting a portion of their annual retainer or meeting fees.

Related Party Transactions

• Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 4.668 shares of common stock from the company through a deferred compensation plan, which is a transaction between a company and its director.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders by increasing her equity stake, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Settlement of the acquired stock units into common stock upon Gabrielle Sulzberger's separation from service with Eli Lilly & Co.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director defers cash compensation into company stock. While it indicates alignment of interests, the transaction size is small relative to the company's market capitalization and does not provide new fundamental information to warrant a change in investment recommendation. It is a standard corporate governance practice that does not significantly alter the investment thesis for Eli Lilly.

Keywords

Eli Lilly, LLY, Insider Transaction, Form 4, Director Compensation, Stock Units, Deferred Compensation, Gabrielle Sulzberger